ICRA has withdrawn the ₹1,500 crore Commercial Paper rating (A1+) for Mankind Pharma at the company’s request; other ratings (AA+/Stable for NCDs and fund-based limits) remain in effect.
AI Assistant
Mankind Pharma Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.